Minimum effective dose for antidepressants - An obligatory requirement for antidepressant drug evaluation?

International Clinical Psychopharmacology

Volumn 11, Issue 3, 1996, Pages 177-185

  Benkert, O ^a   Szegedi, A ^a   Wetzel, H ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Antidepressants; Drug registration; Efficacy evaluation; Methodology; Minimum effective dose

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; DEPRESSION; DRUG DOSE; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029852799     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199609000-00004     Document Type: Article

References (58)

1. Altamura AC, Montgomery SA and Wernicke JF (1988) The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. British Journal of Psychiatry, 153(suppl. 3), 109-112.
2. Angst J, Amrein R and Stabl M (1995) Moclobemide and tricyclic antidepressants in severe depression: metaanalysis and prospective studies. Journal of Clinical Psychopharmacology, 15(suppl. 2), 16S-23S.
3. Beasley CM Jr, Bosomworth JC and Wernicke JF (1990) Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacology Bulletin, 26, 18-24.
4. Benkert O, Gründer G, Wetzel H and Hackett D (1996b) A randomised double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research (in press).
5. Benkert O, Szegedi A, Wetzel H, Staab HJ and Philipp M (1996) Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed outpatients with insufficient treatment response. Acta Psychiatrica Scandinavica (in press).
6. Burch JE, Ahmed O and Hullin RP (1988) Antidepressant effect of amitriptyline treatment with plasma drug levels controlled within three different ranges. Psychopharmacology, 94, 197-205.
7. Burrows GD, Davies B and Scoggins BA (1972) Plasma concentrations of nortriptyline and clinical response in depressive illness. Lancet, 2, 619-623.
8. D'Amico MF, Roberts DL, Robinson DS, Schwiderski UE and Copp J (1990) Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacology Bulletin, 26, 147-150.
9. Davis JM, Janicek PG, Wang Z, Gibbons RD and Sharma RP (1992) The efficacy of psychotropic drugs: implications for power analysis. Psychopharmacology Bulletin, 28, 151-155.
10. Dawling S (1982) Monitoring of tricyclic antidepressant therapy. Clinical Biochemistry, 15, 56-61.
11. Dechant KL and Clissold SP (1991) Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs, 41(suppl. 2), 225-253.
12. Dunbar GC and Stoker MJ (1991) Paroxetine in the treatment of melancholic and severely depressed hospitalized patients. European Neuropsychopharmacology, 1, 439.
13. Dunlop SR, Dornseif BE, Wernicke JF and Potvin JH (1990) Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacology Bulletin, 26, 173-180.
14. Dunner DL and Dunbar GC (1992) Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry, 53(suppl.), 21-26.
15. Fitton A, Faulds D and Goa KL (1992) Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs, 4, 561-596.
16. Fluoxetine Bulimia Nervosa Collaborative Study Group (FBNCSG) (1992) Fluxoetine in the treatment of bulimia nervosa. Archives of General Psychiatry, 49, 139-147.
17. Glassman AH, Perel JM and Shostak M (1977) Clinical implications of imipramine plasma levels for depressive illness. Archives of General Psychiatry, 34, 197-204.
18. Gram LF (1990) Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clinical Neuropharmacology, 13(suppl. 1), 35-44.
19. Gram LF (1994) Fluoxetine. New England Journal of Medicine, 331, 1354-1361.
20. Greenblatt DJ, Abernethy DR and Chaikin P (1994) Pharmacologie considerations. In: Clinical Evaluation of Psychotropic Drugs (Eds RF Prien and DS Robinson), pp. 123-138. Raven Press, New York.
21. Jenner PN (1992) Paroxetine: an overview of dosage, tolerability and safety. International Clinical Psychopharmacology, 6, 69-80.
22. Jerling M, Bertilsson L and Sjoqvist F (1994) The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Therapeutic Drug Monitoring, 16, 1-12.
23. Klerman GL, Weissman MM, Frank E, Kocsis JH, Markowitz JC and Montgomery S (1994) Evaluating drug treatments of depressive disorders. In: Clinical Evaluation of Psychotropic Drugs (Eds RF Prien and DS Robinson), pp. 281-326. Raven Press, New York..
24. Laska EM, Klein DF, Lavori PW, Lavori PW, Levine J and Robinson DS (1994) Design issues for the clinical evaluation of psychotropic drugs. In: Clinical Evaluation of Psychotropic Drugs (Eds RF Prien and DS Robinson), pp. 29-67. Raven Press, New York.
25. Mendels J, Johnston R, Mattes J and Reisenberg R (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacology Bulletin, 29, 169-174.
26. Montgomery DB, Roberts A, Green M, Bullock T, Baldwin D and Montgomery SA (1994) Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. European Archives of Psychiatry and Clinical Neurosciences, 244, 211-215.
27. Montgomery SA (1995) Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. International Clinical Psychopharmacology, 10(suppl. 1), 23-27.
28. Montgomery SA, Rasmussen JGC, Lyby K, Connor P and Tanghoy P (1992) Dose response relationship of citalopram 20 mg, citalopram 40 mg, and placebo in the treatment of moderate and severe depression. International Clinical Psychopharmacology, 6(suppl. 5), 65-70.
29. Montgomery SA, Pedersen V, Tangoy P, Rasmussen C and Rioux P (1994a) The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. International Clinical Psychopharmacology, 9, 35-40.
30. Montgomery SA, Henry J, MacDonald G et al. (1994b) Selective serotonin uptake inhibitors: meta-analysis of discontinuation rates. International Clinical Psychopharmacology, 9, 47-53.
31. Murdoch D and McTavish D (1994) Sertraline: a review of its pharmacological properties and therapeutic use in depression and obsessive-compulsive disorder. Drug, 43, 604-624.
32. Nierenberg AA, Feighner JP, Rudolph R, Cole JO and Sullivan J (1994) Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psychopharmacology, 14, 419-423.
33. Palmer KJ and Benfield P (1994) Fluvoxamine. An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs, 1, 57-87.
34. Paykel ES, Hollyman JA, Freeling P and Sedgwick P (1988) Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. Journal of Affective Disorders, 14, 83-95.
35. Perry PJ, Pfohl BM and Holstad SG (1987) The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis. Clinical Pharmacokinetics, 12, 381-392.
36. Perry PJ, Zeilmann C and Arndt S (1994) Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. Journal of Clinical Psychopharmacology, 14, 230-240.
37. Preskorn SH (1993) Pharmacokinetics of psychotropic agents: why and how they are relevant to treatment. Journal of Clinical Psychiatry, 54(suppl. 9), 14-34.
38. Preskorn SH and Fast GA (1991) Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry, 52(suppl. 6), 23-33.
39. Preskorn SH, Dorey RC and Jerkovich GS (1988) Therapeutic drug monitoring of tricyclic antidepressants. Clinical Chemistry, 34, 822-828.
40. Preskorn SH, Janicak PG, Davis JM and Ayd FJ (1995) Advances in the pharmacotherapy of depressive disorders. In: Principles and Practice of Psychopharmacotherapy, Vol. 1, No. 2 (Eds PG Janicak, JM Davis, SH Preskorn and FJ Ayd). Baltimore Williams and Wilkins.
41. Quitkin FM, Rabkin JG, Ross D and McGrath P (1984) Duration of antidepressant drug treatment. What is an adequate trial? Archives of General Psychiatry, 41, 238-245.
42. Quitkin FM, McGrath PJ, Stewart JW et al. (1990) Atypical depression, panic attacks, and response to imipramine and phenelzine: a replication. Archives of General Psychiatry, 47, 935-941.
43. Quitkin FJ, Harrison W, Stewart JW et al. (1991) Response to phenelzine and imipramine in placebo nonresponders with atypical depression. Archives of General Psychiatry, 48, 319-323.
44. Rickels K, Noyes R, Robinson DS, Schweizer E and Uhlenhuth EH (1994) Evaluating drug treatments of generalized anxiety disorder and adjustment disorders with anxious mood. In: Clinical Evaluation of Psychotropic Drugs (Eds RF Prien and DS Robinson), pp. 373-410. Raven Press, New York.
45. Robinson DS, Marcus RN, Archibald DG and Hardy SA (1996) Therapautic dose range of nefazodone in major depression. Journal of Clinical Psychiatry 57(suppl 2), 6-9.
46. Roose SP, Glassman AH, Attia E and Woodring S (1994) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. American Journal of Psychiatry, 151, 1735-1739.
47. Rudolph R, Entsuah R and Derivan A (1991) Early clinical response in depression to venlafaxine hydrochloride (abstract). Biological Psychiatry, 29, 630S.
48. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G and Weise C (1990) What constitutes an adequate trial for fluoxetine? Journal of Clinical Psychiatry, 51, 8-11.
49. Shrivastava R, Patrick R, Scherer N and Upton GV (1994) A dose-response study of venlafaxine (abstract). Neuropsychopharmacology, 10(suppl.), 221.
50. Szegedi A, Wetzel H, Fickinger MP, Angersbach D, Philipp M and Benkert O (1995) Paroxetine vs. maprotiline in outpatients with major and minor depression (abstract). Pharmacopsychiatry, 28, 221.
51. Tasker TCG, Kaye CM, Zussman BD and Link CGG (1990) Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatrica Scandinavica, 80(suppl. 350), 152-155.
52. Thompson C and Lane R (1994) Sertaline 50 mg: optimal daily dose in depression (abstract). Neuropsychopharmacology, 10(suppl.), 222S.
53. Tollefson GD, Rampey AH, Potvin JH et al. (1994) A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive compulsive disorder. Archives of General Psychiatry, 51, 559-567.
54. Turner RD, Coryell WH and Sherman A (1987) Desipramine plasma levels and clinical response: evidence for a curvilinear relationship. Journal of Clinical Psychopharmacology, 7, 138-142.
55. van Harten J (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics, 24, 203-220.
56. Wernicke JF, Dunlop SR, Dornseif BE and Zerbe RL (1987) Fixed-dose fluoxetine therapy for depression. Psychopharmacology Bulletin, 23, 164-168.
57. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC and Humbert M (1988) Low-dose fluoxetine therapy for depression. Psychopharmacology Bulletin, 24, 183-188.
58. Wilde MI, Plosker GL and Benfield P (1993) Fluvoxamine. An updated review of its pharmacology and therapeutic use in depressive illness. Drugs, 46, 895-924.